Biochemistry major mixes science with outreach – Purdue Agricultural Communications

Thursday, July 6th, 2017

By Mikaela Wieland

Most days, Austin Dixon can be found in the dimly lit basement of the Biochemistry Building, surrounded by expensive, high-tech equipment studying proteins for his undergraduate research project.

On other days, he can be found in a bright classroom, demonstrating how to make a rudimentary lava lamp out of Alka-Seltzer tablets to a group of loud elementary school students. In both environments, Dixon thrives because he shares his love of science with the world.

Science gives me the tools and understanding to answer questions about the world we live in, said Dixon, a senior in biochemistry from Greenwood, Indiana. It provides a platform of discovery to move the world forward.

Photo by Mikaela Wieland Austin Dixon works in the laboratory on an uncharacterized class of proteins. His love for science influences everything from his undergraduate research to his volunteer work with middle schoolers.

It isnt enough that he pursues his research goals on his own. Dixon said the next generation must be inspired to discover great things as well. He teaches in classrooms and judges science fairs. Both volunteer efforts are aimed to engage kids and spark their interest in science.

Often, science is something most kids see as dull or uninteresting, Dixon said. Doing this has allowed me to positively influence younger kids and change their perspective on science.

One of the experiments aimed to pique the middle schoolers interest is the Alka-Seltzer lava lamp.

Its a great way to teach them how something they already know about really works, he said.

The kids mix vegetable oil and water with food coloring and an Alka-Seltzer tablet. The experiment demonstrates simple concepts like density and polarity. The tablets produce carbon dioxide bubbles that are less dense than oil and rise to the top of the lamp.

The kids think its really cool to learn from college kids, Dixon said. And, they love hands-on stuff.

The Purdue Biochemistry Club isnt Dixons only outreach. He judges K-12 science projects at the Indiana Regional Science Fair Competition in West Lafayette and volunteers at the annual Celebrate Science Indiana in Indianapolis. At these events, he interacts with and teaches science to more than 1,000 kids.

Im able to interact with hundreds of young, budding scientists and discuss their projects with them, Dixon said.

Dixons outreach mission is to cultivate the next generation of scientists.

These programs are necessary to get children interested in science beyond the textbook, and open their mind to the possibility of pursuing the field in the future, he said.

Dixon knows that the kids arent the only ones benefitting from the experience.

Its rewarding to me personally because Im able to make an impact in my community and within the lives of these children, which they will remember forever, he said.

Positive memories and experiences associated with science are important, Dixon said, because he wants people to understand the benefit of scientific research and the scientific process. He also wants to erase the stigma associated with science. Dixon said that requires a dialogue with the public that needs to be more transparent and more people need to know how long and detailed of a process science is.

Part of that starts with the way he speaks about his own research. He said that he tries to make sure to explain that his work has a practical use.

You have to talk about the why, he said. People care about what the impact of the science is.

Visit link:
Biochemistry major mixes science with outreach - Purdue Agricultural Communications

This Study Could Help Extend the Human Lifespan – Futurism

In BriefResearchers have identified a single gene deletion in E. colibacteria that influence longevity in C. elegans worms. This pointsto the role of gut bacteria in life extension and points to thepossibility of a life-extending probiotic in the future.

Researchers at the Baylor College of Medicine have found the key to longevity in Caenorhabditis elegans (C. elegans) worms and maybe, someday, humans. The team noticed that genetically identical worms would occasionally live for much longer, and looked to their gut bacteria to find the answer. They discovered that a strain of E. coli with a single gene deletion might be the reason that its hosts lives were being significantly extended.

This study is one among a number of projects that focus on the influence of the microbiome the community of microbes which share the body of the host organism on longevity. Ultimately, the goal of this kind of research is to develop probiotics that could extend human life. Ive always studied the molecular genetics of aging, Meng Wang, one of the researchers who conducted the study, told The Atlantic. But before, we always looked at the host. This is my first attempt to understand the bacterias side.

Even in cases like this, where it seems fairly obvious that the microbiome is influencing longevity, parsing out the details of how and why this happens among a tremendous variety of chemicals and microbe species is extremely complex. The team, in this case, was successful because they simplified the question and focused on a single relationship.

Genetically engineering bacteria to support and improve human health and even to slow aging and turning it into a usable, life-extending probiotic wont be easy. It is extremely difficult to make bacteria colonize the gut in a stable manner, which is a primary challenge in this field. The team, in this case, is looking to the microbiome, because the organisms used would be relatively safe to use because they would originate in the gut.

Clearly, researchers dont know yet whether these discoveries will be able to be applied to people, though it seems promising. Despite the obvious differences between the tiny C. elegans worm and us, its biology is surprisingly similar; many treatments that work well in mice and primates also work in the worm. The team will begin experiments along these same lines with mice soon.

Other interesting and recent research hoping to stop or slow the march of time includes work with induced pluripotent stem (iPS) cells, antioxidants that target the mitochondria, and even somewhat strangework with cord blood. It seems very likely that we wont have a single solution offering immortality anytime soon, but instead a range of treatment options that help to incrementally hold back time. And, with an improving quality of life, this kind of life extension sounds promising.

Read the original post:
This Study Could Help Extend the Human Lifespan - Futurism

10th International Conference on Genomics and Pharmacogenomics – Technology Networks

Theme: Advanced Approaches in Genomics and Pharmacogenomics

It gives us immense pleasure to announce the conference that is 10th International Conference on Genomics & Pharmacogenomics.

Genomics 2018 will provide a perfect platform to all the Scientists, Researchers, Students and Business Delegates to approach and deliver all the attendees about the latest scientific advancements on the respective sphere.

Genomics 2018 Genomics is an area within genetics that concerns the sequencing and analysis of an organisms genome. Genomics also involves the study of intragenomic processes such as epistasis, heterosis and pleiotropy as well as the interactions between loci and alleles within the genome. The fields of molecular biology and genetics are mainly concerned with the study of the role and function of single genes, a major topic in todays biomedical research. By contrast, genomics does not involve single gene research unless the purpose is to understand a single genes effects in context of the entire genome

Conference Highlights: Cancer Genomics, Functional Genomics, Next Generation Sequencing, Biomarkers & Molecular Markers, Pharmacogenomics & Personalized Medicine, Clinical Genomics, Micro RNAm, RNA Analysis, Bioinformatics in Genomics, Comparative Genomics, Plant Genomics, Genome Engineering, Microbial Genomics, Future trends in Genomics, Genome Medicine, and Genomics Market

Link of the conference: http://genomics.conferenceseries.com/

Conference Mail ID: genomics@conferenceseries.net, genomics@geneticconferences.com

Like what you just read? You can find similar content on the communities below.

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

Visit link:
10th International Conference on Genomics and Pharmacogenomics - Technology Networks

News from the American Headache Society Annual Meeting: Positive Trial Results for Anti-migraine Drugs Targeting … – LWW Journals

Robinson, Richard

doi: 10.1097/01.NT.0000521716.95578.ef

Features

In large clinical trials, researchers reported that four calcintonin-gene related peptide antibodies three that bind to the peptide itself, and one that binds to the receptor were safe and effective for reducing migraine days.

BOSTONThe mood at the American Headache Society (AHS) annual scientific meeting here in June was decidedly upbeat, with experts in the field declaring a paradigm shift and the start of a new era in the treatment of migraine. The excitement was generated by announcements of positive trial results across the board for four antibodies, from four competing companies, targeting the calcitonin gene-related peptide (CGRP) or its receptor.

Three agents eptinezumab from Alder Biosciences, fremanezumab from Teva, and galcanezumab from Lilly bind to the peptide itself, while erenumab, from Amgen, binds to the receptor. While not all the companies have submitted data for final regulatory review, all have completed large-scale trials, and all, according to results presented at the meeting, met their primary and secondary endpoints rapid, significant, and long-lasting relief of migraine with adverse-effect profiles identical or close to placebo.

We are about to enter an era where we have preventive treatments specifically for migraine. We are standing at the edge of an incredible development, predicted Peter Goadsby, MD, PhD, FAHS, professor of neurology at Kings College London and chair of the AHS science program committee.

CGRP was discovered in the early 1980s as an alternatively-spliced transcript of the calcitonin gene. Soon thereafter it was found to be abundantly produced by trigeminal nerve endings, and was elevated during migraine attacks. While the exact pathophysiological role of CGRP in migraine remains unknown, it is clear that its elevation and interaction with its receptor directly contributes to migraine intensity, through enhancing both peripheral and central nociception pathways, possibly through increasing mast cell degranulation, neurogenic inflammation, and vasodilation.

Small-molecule CGRP antagonists were developed early on, but have been limited by concerns over adverse effects, including liver toxicity. That set the stage for development of monoclonal antibodies targeting either the peptide of its receptor.

None of the four monoclonal antibodies against the CGRP system are immunomodulatory, since their target is not the immune system. A small percentage of patients, ranging from 1 percent to 14 percent, depending on the drug and the study, do carry antibodies against the monoclonal antibody, but so far none has been shown to affect the ability of the treatment to reduce migraine.

The clinical programs for the four agents have proceeded rapidly, culminating in the recently completed phase 3 trials announced at the AHS meeting.

A single dose of eptinezumab reduced migraine days by 75 percent after three months in a third of patients with chronic migraine, according to the results of a phase 2B trial presented here. The trial enrolled 616 patients who had 15 to 28 headache days per month, at least eight of which were migraine. As in each of the other studies presented at the meeting with monoclonals targeting the CGRP system, patients were primarily female, with a history of migraine often of a decade or more.

Patients received a single intravenous dose of eptinezumab (300 mg, 100 mg, 30 mg, or 10 mg) or placebo. The primary endpoint was the percentage of patients with a 75% or greater reduction in migraine days over three months.

At baseline, patients had 16 migraine days per month. The primary endpoint was achieved by 33 percent of patients in the 300-mg dose group and 31 percent of those in the 100-mg group, versus 21 percent receiving placebo (both comparisons p<0.05).

Neither of the low-dose groups were different from placebo. In a post-hoc analysis, there was a dose-dependent reduction in the severity of migraine compared to placebo as well, and the separation from placebo for frequency began to appear within the first 24 hours of treatment.

It might not just be frequency that is affected, said Jeffrey Smith, MD, lead author and senior vice president at Alder. This is an exploratory endpoint, but it may be important as well. In addition, he noted, migraine reduction was extremely rapid, with a separation from placebo beginning to appear within the first 24 hours of treatment.

Eptinezumab is now in phase 3 trials, with the final results expected in early 2018.

Sheena Aurora, MD, a medical fellow and global launch leader at Eli Lilly Company, reported that monthly injections with galcanezumab reduced headache days by an average of four days per month for six months, compared to two days for placebo, according to results from a phase 3 trial that enrolled more than 900 patients. Participants were randomized 2:1:1 to placebo or galcanezumab at 120 mg or 240 mg, delivered by subcutaneous injection once monthly for six months. At baseline, patients had about nine migraine headache days per month.

After six months, patients on placebo had a decline in mean migraine headache days of 2.25 days, while those on galcanezumab declined by 4.29 days at 120 mg and 4.18 days at 240 mg. Both were significant compared to placebo at p<0.001. Both doses outperformed placebo at each monthly assessment.

In a secondary analysis, there were significantly more patients on active treatment who achieved a 50 percent or more reduction in the number of migraine headache days 36 percent of those on placebo compared with 59 percent for those taking 120 mg and 56 percent, 240 mg as well as a 75 percent or more reduction (18 percent of those on placebo; 33 percent on 120 mg, and 34 on 240 mg. Injection-site reactions were more common in active treatment than placebo. Eli Lilly, which is developing the drug, is planning to submit data for approval to the US Food and Drug Administration (FDA) later this year.

Patients receiving a single injection of fremanezumab began to experience relief within one week of administration, and continued to experience significant reduction in migraine for up to three months compared to placebo, according to data from a phase 3 trial presented here.

The trial included three arms: placebo injections once a month for three months; a single 675 mg subcutaneous injection of fremanezumab, followed by two monthly placebo injections (designed to test the efficacy of quarterly injections); and one 675 mg injection of fremanezumab followed by two monthly injections of 225 mg fremanezumab.

The primary endpoint was the change from baseline in the number of monthly headache days of at least moderate severity over three months: 1,130 patients were randomized 1:1:1 to each of the three treatment arms.

Placebo-treated patients experienced an average of 2.5 fewer headache days per month during the study. Monthly headache days declined by 4.6 days in patients receiving monthly fremanezumab, and by 4.3 days in those receiving the single dose (both results p<0.001 versus placebo). Injection-site effects were similar in placebo and active-treatment groups.

Active treatment was associated with at least a 50% reduction in headache days in 41% of those on monthly treatment and 38% of those on quarterly treatment, versus 18% on placebo (both results p<0.001 versus placebo). Benefits emerged within one week of initial treatment.

In patients with chronic migraine, erenumab reduced monthly migraine days by 6.6 days, versus 4.2 days for placebo, according to a phase 3 study presented here. Successful phase 3 trials of erenumab for episodic migraine have been previously presented.

To test its potential in chronic migraine, defined as headache for 15 or more days per month, and migraine for eight or more days per month, investigators enrolled 667 patients, randomized 3:2:2 to monthly placebo, erenumab 70 mg or erenumab 140 mg, administered subcutaneously. The primary endpoint was the change from baseline in monthly migraine days over three months of treatment, a measure meant to account for expected month-to-month fluctuations in severity.

The researchers used the mean of the three months, rather than the reduction in the final month, because experience has shown that the response rate fluctuates somewhat from month to month, said the lead investigator, Stewart J. Tepper, MD, FAHS, professor of neurology at the Geisel School of Medicine at Dartmouth in Hanover, NH.

At baseline, patients in each group had a mean of 18 monthly migraine days. Both doses of erenumab reduced that by a mean of 6.6 days, versus 4.2 days for placebo (p<0.001 for both). Active treatment was also associated with a greater response rate, with 40 percent and 41 percent in the low- and high-dose groups experiencing a 50 percent or greater reduction in monthly migraine days, versus 23 percent for placebo (p< 0.001 for both).

Adverse event profiles were similar for active treatment and placebo, except for a small increase in injection-site pain in those receiving erenumab. The results of the trial were published recently in June in Lancet Neurology. The company has submitted data to the FDA for an indication for both episodic and chronic migraine.

The results reported for these drugs are very exciting, commented Kathleen B.Digre, MD, FAAN, professor of neurology and ophthalmology and director of the division of headache and neuro-ophthalmology at the University of Utah in Salt Lake City. The safety profile looks very promising, compared to current preventive treatments, and the speed of response is extraordinary, she said. Typically we've needed to wait four to eight weeks to see a response, whereas each of the CGRP antibodies appear to show some kind of signal by one week. That's remarkable.

David W. Dodick, MD, FAAN, professor of neurology at the Mayo Clinic in Scottsdale, AZ, said that, because of their ease of administration and tolerability, the monoclonals are likely to greatly improve adherence over current migraine preventives. This is going to be changing the way neurologists practice.

Stephen D. Silberstein, MD, FAAN, professor of neurology and director of the Headache Center at Jefferson University Hospital at Thomas Jefferson University in Philadelphia, said, I would look at them all as a group. They are all effective, and they all look safe and tolerable.

Absent head-to-head studies, he continued, it is difficult to determine what nuances there may be between these drugs. Instead, the global message from these trials is that we have a new series of drugs that are powerful and effective, and have a side-effect profile similar to placebo. For one of the most disabling of disorders, which affects millions of people in their most productive years, this allows hope.

Link:
News from the American Headache Society Annual Meeting: Positive Trial Results for Anti-migraine Drugs Targeting ... - LWW Journals

Nas Feeling Whipped On Nicki Minaj After ‘Great Sexual Chemistry … – Hollywood Life

Nicki Minaj has Nas Anaconda feeling some type of way! Hes whipped on the raptress after their great sexuality chemistry and cant wait see her again, HollywoodLife.com has EXCLUSIVELY learned.

Nas, 43, can tell that Nicki Minaj, 34, aint missing no meals. Even though the couple broke up earlier this week, the Made You Look rapper cant their intense sexual attraction out of his head. Nas is feeling whipped on Nicki and its a feeling hes not familiar with, a source tells HollywoodLife.com EXCLUSIVELY. They have great sexual chemistry and he wants some more hot times with her. The problem is that shes super busy in the studio working on her overdue album and hasnt made him a priority. Yeah, that and the fact that he liked a bunch of Meek Mill rants on Instagram.

Fans first suspected that Nas and the Anaconda songstress split based on his social media behavior. Meek went on ANOTHER anti-Nicki rampage and Nas actually supported it! Thats not what a boyfriend does! In any case, he ended up feeling totally depresso afterwards and is now looking for any reason to start things up again, even if its strictly sexual with no deep emotions involved. Nas made it clear to Nicki that he wants to see her again and right now, the source continues. He hasnt seen her in a hot minute and feels dissed.

Well, the Beef actor better quit all this moping around crap before Nicki says goodbye forever. She hates when a dude shows his weak side to the public! His latest emo Instagram picture majorly turned her off! She told him to man up, a different insider EXCLUSIVELY told us. If he wants her to be his Queen he needs to act like a King. Preach, sister!

HollywoodLifers, would you like to see Nas and Nicki hook up again?

Visit link:
Nas Feeling Whipped On Nicki Minaj After 'Great Sexual Chemistry ... - Hollywood Life

UT Dallas Chemistry Professors Receive Welch Foundation Grants – University of Texas at Dallas (press release)

Text size: research

July 10, 2017

Two UT Dallas faculty members in the Department of Chemistry and Biochemistry Dr. Sheel Dodani BS07 and Dr. Gabriele Meloni are recipients of three-year, $195,000 grants from the Welch Foundation to support research geared toward improving the understanding of cellular function.

Dodanis research focuses on the development of imaging technologies that would allow us to better understand how anions, negatively charged atoms such as chloride, contribute to human health and diseased states such as cystic fibrosis, cancer and chronic pain.

Directly visualizing the chloride anion itself has been limited by technical challenges, Dodani said. Turn-on fluorescence imaging approaches could revolutionize the field but remain largely underdeveloped. If successful, we will not only define the design criteria required for the detection of chloride and other anions in water but will also provide a more complete picture of how cells spatially and temporally position chloride for biological function.

Melonis work involveslearning more about how transition metals some of which are essential for cell metabolism while others are severely toxic are selectively transported across cellular membranes by specific transporter proteins.

We expect this work help establish a new line of groundbreaking research in a neglected aspect of bioinorganic chemistry, Meloni said. Revealing the coordination chemistry involved in transition metals transporter-mediated cellular transport will significantly contribute to our understanding of how metal substrates are recognized and translocated across lipid bilayers and biological membranes.

Founded in 1954, the Houston-based Welch Foundation is one of the nations largest private funding sources for basic chemistry research through research grants, departmental programs, endowed chairs and other special projects at educational institutions in Texas. With Dodanis and Melonis grants, UT Dallas now has eight active Welch grants.

The foundation also renewed grants to Dr. Dean Sherry, the Cecil H. and Ida Green Distinguished Chair in Systems Biology; Dr. Jung-Mo Ahn, associate professor of chemistry and biochemistry; and physics professor Dr. Anvar Zakhidov. Additionally, faculty members Dr. Kenneth Balkus, Dr. Lloyd Lumata and Dr.Mihaela Stefan have ongoing projects funded by the foundation.

Media Contact: Stephen Fontenot, UT Dallas, (972) 883-4405, [emailprotected] or the Office of Media Relations, UT Dallas, (972) 883-2155, [emailprotected]

Read more:
UT Dallas Chemistry Professors Receive Welch Foundation Grants - University of Texas at Dallas (press release)

Taking time off in medical school – Scope (blog)

Like many of my classmates, I took the last year off from medical school. Some of us enrolled in different graduate programs to pursue a dual degree while others did a research year. The trend is becoming more common the proportion of students who take more than four years to graduate and the number in dual degree programs are at all-time highs.

Over the past few months, several students have asked me about my experience and whether I would recommend they do the same. While the short answer is, It depends, I think there are three questions worth thinking about while deciding whether towalk away from medical school for a year.

What do you want to get out of taking time off?

This first question sounds obvious but goes unanswered surprisingly often. Anecdotally, many people take time off because everyone else is doing it. A majority of Stanford med students take 5+ years to graduate, creating a social norm around taking an additional year.

Its important to pause and consider what exactly you want to achieve during this time. In my case, I wanted to develop new skills and obtain a degree that would serve my professional interests. Other commonly cited reasons include increasing competitiveness for residency or personal factors.

Of course, its possible to develop skills, build a competitive residency application, and more in the traditional four years of medical school. Most schools (including Stanford) also provide a substantial amount of elective time during the fourth year. We can use this time for the same type of personal development that many students prioritize during a year off. Its therefore helpful to articulate how you will be different at the end of your time off compared to when you started.

What is the best way to achieve your goals?

If youve decided that you have compelling reasons to take time off, the next question is how to achieve your goals. I think there are two critical decisions. The first is whether to do a degree program (e.g. MBA, MPH, etc.) or to work full-time (with work meaning research, an internship, or starting an organization, among other possibilities). A degree carries the advantage of formal teaching and would offer an additional credential. But at the same time, it requires you to spend a certain amount of time going to classes and doing homework and that time might be better spent elsewhere.

The second decision is whether you want to take just one year off or are willing to step away from med school for multiple years. This choice affects what options are available. For example, some degrees can be completed with one additional year of school while others require multiple (e.g. PhD, some Masters degrees). Similarly, some projects can be completed quickly while others have multi-year time horizons. All those considerations must be taken into account.

How will you stay connected to the medical school during your time away?

Finally, its important to reflect on the relationship you will have with medicine during your time off. In some cases, it is easy to stay engaged with the medical school many students doing clinical research work with the same physician mentors and continue to interact with patients on a regular basis. But students who leave the medical school environment (e.g. to do an MD/MBA, work in an external job, etc.) must think about how to stay connected, whether it is through ongoing research projects, a continuity clinic, or something else.

The ability to take time off and pursue other interests during medical school is a privilege. But before acting on it, students should give careful thought to how to make the most of the opportunity.

Stanford Medicine Unplugged is a forum for students to chronicle their experiences in medical school. The student-penned entries appear on Scope once a week; the entire blog series can be found in the Stanford Medicine Unpluggedcategory.

Akhilesh Pathipati is a fourth-year MD/MBA student at Stanford. He is interested in issues in health care delivery.

Photo by Pixabay

Link:
Taking time off in medical school - Scope (blog)

Nanotechnology, Smart Textiles & Wearables – PR Newswire – PR Newswire (press release)

LONDON, July 6, 2017 /PRNewswire/ -- Key findings in the report include - Opportunities in smart textiles will overtake those in apparel within six years

Download the full report: https://www.reportbuyer.com/product/4736143/

- Compound annual growth rates range from 14% in to 167% depending on the application - The value of nanomaterials used by the global textile industry will rise sharply from several hundred million dollars currently driven by the additional functionality demanded by smart textiles and wearables

Cientifica have been monitoring nanotechnology and smart textiles for over a decade and the report ranges from the latest advances in wearables to the use of nanofibers in dust and water filtration.

Nanotechnology, Smart Textiles & Wearables is the most up to date and comprehensive look at the sector and its 207 pages discuss over 250 companies active in the space.

Key Sections include: Smart Textiles, Wearable Technologies and the 4th Industrial Revolution; looking at how textiles and computing are converging and the factors driving this.

Markets; analyzing the global market for nanotechnology and smart textiles by application area. This section looks at apparel, home textiles, medical textiles, military textiles, technical textiles and textile based wearables. It also provides figures for the nanomaterials inputs (materials, coatings, inks, masterbatches etc.) required for each application.

Nanotechnology and Graphene In Textiles; examining why these materials are being used in textiles and what advantages they confer.

Applications; giving detailed description of current and proposed applications of nanotechnology by sector and covers Clothing and Apparel, Sports and Wellbeing , Energy Storage and Generation , Energy Harvesting , Fashion, Entertainment, Personal Protection, Military Textiles., Home Textiles, Medical Textile and Technical textiles.

Download the full report: https://www.reportbuyer.com/product/4736143/

About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com

For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: http://www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nanotechnology-smart-textiles--wearables-300484257.html

Visit link:
Nanotechnology, Smart Textiles & Wearables - PR Newswire - PR Newswire (press release)

Minocyline Found to Have a Role in Early MS Treatment – LWW Journals

Fitzgerald, Susan

doi: 10.1097/01.NT.0000521713.03202.29

Features

A new study found that minocycline may slow the progression of multiple sclerosis (MS) in patients who have early signs of the disease, but independent MS experts disagree about the efficacy of the treatment.

Minocycline, an inexpensive decades-old antibiotic, may slow the progression of multiple sclerosis (MS) in patients who have early signs of the disease, according to a randomized, controlled trial reported in the June 1 issue of The New England Journal of Medicine.

The study found that minocycline reduced the risk of conversion from a first demyelinating event, also known as clinically isolated syndrome (CIS), to a diagnosis of MS compared with placebo over six months.

Minocycline, traditionally used to treat severe acne, has been shown in animal and laboratory studies to have anti-inflammatory and neuroprotective effects, and a few smaller human trials suggested it may have a place in MS treatment, either alone or in combination with other drugs. The results from this new trial conducted in Canada created a buzz in the MS community, but opinions vary on whether minocycline is poised to become part of the standard lineup of MS drugs.

The study, funded by the Multiple Sclerosis Society of Canada and carried out at 12 Canadian MS clinics, was designed to assess whether minocycline reduced the risk of conversion from a first clinical demyelinating event to a diagnosis of MS as defined by the 2005 McDonald criteria, which were in effect when the study began in 2009. Patients were eligible for the study if they had had a single clinically isolated demyelinating event such as optic neuritis or a brainstem, cerebral, cerebellar or myelopathy syndrome within the previous 180 days, and had at least two lesions larger than 3 mm in diameter on T2-weighted magnetic resonance imaging (MRI) of the brain. (One lesion had to be ovoid, periventricular or infratentorial, which is typical of demyelinating disease.)

A total of 142 patients were randomized to 100 mg of minocycline twice daily (72) or placebo (70). The primary endpoint was conversion to MS based on the 2005 McDonald criteria within six months. Secondary outcomes included conversion to MS within 24 months and changes on MRI at six months and 24 months change in lesion volume on T2-weighted MRI, cumulative number of new lesions enhanced on T1-weighted MRI, and cumulative combined number of unique lesions.

The unadjusted risk of conversion to MS within six months was 33.4 percent in the minocycline group compared to 61 percent in the placebo group. After adjusting for the number of enhancing lesions at baseline, the risk of conversion at six months was 43 percent for minocycline, 61.5 percent for placebo.

The adjusted risk difference of 18.5 percentage points at 6 months is similar to that with other disease-modifying therapies for multiple sclerosis, reported the researchers, led by Luanne Metz, MD, section chief of neurology and program leader for multiple sclerosis for the University of Calgary and Alberta Health Services.

Analysis of the data was complicated by the fact that during the trial period the 2005 McDonald criteria for MS were replaced by 2010 criteria, which would have reclassified some of the participants in this trial as having multiple sclerosis at the initial presentation, the researchers reported.

Dr. Metz said that minocycline continued to show a positive effect even when that point was taken into consideration. I would say that whatever way we analyzed the data, we came out with similar results, she said.

Those who received minocycline were more likely to drop out of the trial and to have side effects including rash, dizziness and teeth discoloration, though Dr. Metz said such side effects aren't any worse than those found with other therapies and they are not serious.

Dr. Metz said she believed there is now sufficient Level I evidence to support the use of minocycline in early MS treatment, if only as an interim drug as an MS diagnosis is being sorted out.

She noted that MS drugs can cost over $50,000 annually, as opposed to $500 or so for minocycline. Most of the people in the world can't afford those drugs, she said, and minocycline is taken orally, not injected, which is another advantage. If we look globally, minocycline is an important consideration.

Dr. Metz said her team is considering whether to do additional clinical testing of minocycline for either CIS or relapsing-remitting MS, but she said it would be unethical to do a placebo-controlled trial since there are proven treatment options for patients.

Bianca Weinstock-Guttman, MD, professor of neurology at the State University of New York University at Buffalo and director of the Jacobs MS Center for Treatment and Research, said that while the study on minocycline was interesting, it was difficult to imagine this would go further and become a routine part of clinical care. A larger, longer-term study would be needed to further assess the drug's effectiveness for MS, she said, and even then, patients and clinicians would be prone to wanting newer MS drugs.

For now, you really can't go and recommend this to patients, Dr. Weinstock-Guttman told Neurology Today.

On the other hand, Amit Bar-Or, MD, FRCPC, professor of neurology, director of the Center for Neuroinflammation and chief of the multiple sclerosis division at the University of Pennsylvania Perelman School of Medicine, said the study is important and provides a rationale for pursuing minocycline as a potential therapy for MS.

He said the oral antibiotic is generally safe and well-tolerated and is also quite inexpensive compared to the existing MS medications.

Dr. Bar-Or said the minocycline study was a nice example of translational medicine taking laboratory and animal research findings and testing them in the clinical setting. He also complimented the MS Society of Canada for sponsoring the study, an important step because the pharmaceutical industry is typically less attracted to a molecule that will not be sold under patent for a higher price.

Dr. Weinstock-Guttman noted, however, that the exact mechanisms by which minocycline may impact MS are not fully understood, but it is known that the drug can penetrate the blood-brain barrier and research in animal models supports that it has anti-inflammatory, neuroprotective effects. The neuroprotective effect may be related to anti-apoptotic properties and inhibitory activity on microglia, she said. The drug may also help in MS by preventing T-cell migration into the central nervous system, she added.

She said the latest results from Canada still leave many clinical questions unanswered about the potential role of minocycline in MS therapy, including whether the drug in the long run can reduce disease activity and limit disability.

The study, whose enrollment stretched from 2009 to 2013 due to some enrollment difficulties, was in some ways overtaken by advances in MS drug therapy and a growing tendency in MS practice to begin treatment at the earliest possible signs of disease.

A study published last year with 11 years of follow-up found an advantage to starting treatment with interferon beta 1-b at the time of CIS diagnosis instead of waiting until a patient converted to MS. The study did not look at other MS drugs. The dilemma for clinicians is that it's not necessarily easy to predict which patients with will go on to MS, though over two-thirds of people do over a period of eight to ten years.

Emmanuelle Waubant, MD, PhD, FAAN, professor of neurology at the University of California, San Francisco and the Race to Erase MS medical director, said she thought the Canadian results were partially muddled by the fact that the placebo group had more active disease at the beginning, which means they were more likely to convert to MS than the minocycline group.

Dr. Waubant said that at least six new MS drugs have come on the market since the study was launched, all with higher effectiveness and tested over longer periods of time in larger studies. Given that patients now have many options, the likelihood of minocycline becoming commonly used for MS is close to nil, Dr. Waubant said. However, having this proof-of-concept study may help develop new treatment strategies.

In addition to more therapy options, the criteria for diagnosing CIS and MS also continue to evolve, with new revised McDonald criteria in the works, she said.

The landscape is constantly changing, and that is a challenge when you conduct clinical trials, Dr. Waubant said.

See the article here:
Minocyline Found to Have a Role in Early MS Treatment - LWW Journals

Human genetic clustering – Wikipedia

Human genetic clustering is the degree to which human genetic variation can be partitioned into a small number of groups or clusters. A leading method of analysis uses mathematical cluster analysis of the degree of similarity of genetic data between individuals and groups in order to infer population structures and assign individuals to hypothesized ancestral groups. These groupings in turn often, but not always, correspond with the individuals' self-identified geographical ancestry. A similar analysis can be done using principal components analysis,[1] and several recent studies deploy both methods.[2][3]

Analysis of genetic clustering examines the degree to which regional groups differ genetically, the categorization of individuals into clusters, and what can be learned about human ancestry from this data. There is broad scientific agreement that a relatively small fraction of human genetic variation occurs between populations, continents, or clusters. Researchers of genetic clustering differ, however, on whether genetic variation is principally clinal or whether clusters inferred mathematically are important and scientifically useful.

One of the underlying questions regarding the distribution of human genetic diversity is related to the degree to which genes are shared between the observed clusters. It has been observed repeatedly that the majority of variation observed in the global human population is found within populations. This variation is usually calculated using Sewall Wright's fixation index (FST), which is an estimate of between to within group variation. The degree of human genetic variation is a little different depending upon the gene type studied, but in general it is common to claim that ~85% of genetic variation is found within groups, ~610% between groups within the same continent and ~610% is found between continental groups. Ryan Brown and George Armelagos described this as "a host of studies [that have] concluded that racial classification schemes can account for only a negligible proportion of human genetic diversity," including the studies listed in the table below.

(rather than among populations)

diversity[4]

Cavalli-Sforza

microsatellite loci

These average numbers, however, do not mean that every population harbors an equal amount of diversity. In fact, some human populations contain far more genetic diversity than others, which is consistent with the likely African origin of modern humans.[7][8] Therefore, populations outside of Africa may have undergone serial founder effects that limited their genetic diversity.[7][8]

The FST statistic has come under criticism by A. W. F. Edwards[9] and Jeffrey Long and Rick Kittles.[10] British statistician and evolutionary biologist A. W. F. Edwards faulted Lewontin's methodology for basing his conclusions on simple comparison of genes and rather on a more complex structure of gene frequencies. Long and Kittles' objection is also methodological: according to them the FST is based on a faulty underlying assumptions that all populations contain equally genetic diverse members and that continental groups diverged at the same time. Sarich and Miele have also argued that estimates of genetic difference between individuals of different populations understate differences between groups because they fail to take into account human diploidy.[11]

Keith Hunley, Graciela Cabana, and Jeffrey Long created a revised statistical model to account for unequally divergent population lineages and local populations with differing degrees of diversity. Their 2015 paper applies this model to the Human Genome Diversity Project sample of 1,037 individuals in 52 populations.[8] They found that least diverse population examined, the Surui, "harbors nearly 60% of the total species diversity." Long and Kittles had noted earlier that the Sokoto people of Africa contains virtually all of human genetic diversity.[12] Their analysis also found that non-African populations are a taxonomic subgroup of African populations, that "some African populations are equally related to other African populations and to non-African populations," and that "outside of Africa, regional groupings of populations are nested inside one another, and many of them are not monophyletic."[8]

Multiple studies since 1972 have backed up the claim that, "The average proportion of genetic differences between individuals from different human populations only slightly exceeds that between unrelated individuals from a single population."[13][14][15][16][17][18][19]

Edwards (2003) claims, "It is not true, as Nature claimed, that 'two random individuals from any one group are almost as different as any two random individuals from the entire world'" and Risch et al. (2002) state "Two Caucasians are more similar to each other genetically than a Caucasian and an Asian." However Bamshad et al. (2004) used the data from Rosenberg et al. (2002) to investigate the extent of genetic differences between individuals within continental groups relative to genetic differences between individuals between continental groups. They found that though these individuals could be classified very accurately to continental clusters, there was a significant degree of genetic overlap on the individual level, to the extent that, using 377 loci, individual Europeans were about 38% of the time more genetically similar to East Asians than to other Europeans.

Witherspoon et al. (2007) have argued that even when individuals can be reliably assigned to specific population groups, it may still be possible for two randomly chosen individuals from different populations/clusters to be more similar to each other than to a randomly chosen member of their own cluster. Witherspoon et al. conclude that "caution should be used when using geographic or genetic ancestry to make inferences about individual phenotypes". A study of three completely genotyped individuals, white American scientists James Watson and Craig Venter, and Korean scientist Seong-Jin Kim found that the two white scientists have fewer genetic variations (single nucleotide polymorphisms or SNPs) in common than either shares with Kim.[21]

Genetic structure studies are carried out using statistical computer programs designed to find clusters of genetically similar individuals within a sample of individuals. Studies such as those by Risch and Rosenberg use a computer program called STRUCTURE to find human populations (gene clusters). It is a statistical program that works by placing individuals into one of an arbitrary number of clusters based on their overall genetic similarity, many possible pairs of clusters are tested per individual to generate multiple clusters.[22] The basis for these computations are data describing a large number of single nucleotide polymorphisms (SNPs), genetic insertions and deletions (indels), microsatellite markers (or short tandem repeats, STRs) as they appear in each sampled individual. Cluster analysis divides a dataset into any prespecified number of clusters.

These clusters are based on multiple genetic markers that are often shared between different human populations even over large geographic ranges. The notion of a genetic cluster is that people within the cluster share on average similar allele frequencies to each other than to those in other clusters. (A. W. F. Edwards, 2003 but see also infobox "Multi Locus Allele Clusters") In a test of idealised populations, the computer programme STRUCTURE was found to consistently underestimate the numbers of populations in the data set when high migration rates between populations and slow mutation rates (such as single-nucleotide polymorphisms) were considered.[23] In 2004, Lynn Jorde and Steven Wooding argued that "Analysis of many loci now yields reasonably accurate estimates of genetic similarity among individuals, rather than populations. Clustering of individuals is correlated with geographic origin or ancestry."[24]

A number of genetic cluster studies have been conducted since 2
002, including the following:

In a 2005 paper, Rosenberg and his team acknowledged that findings of a study on human population structure are highly influenced by the way the study is designed.[29][30] They reported that the number of loci, the sample size, the geographic dispersion of the samples and assumptions about allele-frequency correlation all have an effect on the outcome of the study.

In a review of studies of human genome diversity, Guido Barbujani and colleagues note that various cluster studies have identified different numbers of clusters with different boundaries. They write that discordant patterns of genetic variation and high within-population genetic diversity "make[] it difficult, or impossible, to define, once and for good, the main genetic clusters of humankind."[7]

A major finding of Rosenberg and colleagues (2002) was that when five clusters were generated by the program (specified as K=5), "clusters corresponded largely to major geographic regions." Specifically, the five clusters corresponded to Africa, Europe plus the Middle East plus Central and South Asia, East Asia, Oceania, and the Americas. The study also confirmed prior analyses by showing that, "Within-population differences among individuals account for 93 to 95% of genetic variation; differences among major groups constitute only 3 to 5%."

Rosenberg and colleagues (2005) have argued, based on cluster analysis, that populations do not always vary continuously and a population's genetic structure is consistent if enough genetic markers (and subjects) are included. "Examination of the relationship between genetic and geographic distance supports a view in which the clusters arise not as an artifact of the sampling scheme, but from small discontinuous jumps in genetic distance for most population pairs on opposite sides of geographic barriers, in comparison with genetic distance for pairs on the same side. Thus, analysis of the 993-locus dataset corroborates our earlier results: if enough markers are used with a sufficiently large worldwide sample, individuals can be partitioned into genetic clusters that match major geographic subdivisions of the globe, with some individuals from intermediate geographic locations having mixed membership in the clusters that correspond to neighboring regions." They also wrote, regarding a model with five clusters corresponding to Africa, Eurasia (Europe, Middle East, and Central/South Asia), East Asia, Oceania, and the Americas: "For population pairs from the same cluster, as geographic distance increases, genetic distance increases in a linear manner, consistent with a clinal population structure. However, for pairs from different clusters, genetic distance is generally larger than that between intracluster pairs that have the same geographic distance. For example, genetic distances for population pairs with one population in Eurasia and the other in East Asia are greater than those for pairs at equivalent geographic distance within Eurasia or within East Asia. Loosely speaking, it is these small discontinuous jumps in genetic distanceacross oceans, the Himalayas, and the Saharathat provide the basis for the ability of STRUCTURE to identify clusters that correspond to geographic regions".[31]

Rosenberg stated that their findings "should not be taken as evidence of our support of any particular concept of biological race (...). Genetic differences among human populations derive mainly from gradations in allele frequencies rather than from distinctive 'diagnostic' genotypes."[25] The study's overall results confirmed that genetic difference within populations is between 93 and 95%. Only 5% of genetic variation is found between groups.[29]

The Rosenberg study has been criticised on several grounds.

The existence of allelic clines and the observation that the bulk of human variation is continuously distributed, has led some scientists to conclude that any categorization schema attempting to partition that variation meaningfully will necessarily create artificial truncations. (Kittles & Weiss 2003). It is for this reason, Reanne Frank argues, that attempts to allocate individuals into ancestry groupings based on genetic information have yielded varying results that are highly dependent on methodological design.[32] Serre and Pbo (2004) make a similar claim:

The absence of strong continental clustering in the human gene pool is of practical importance. It has recently been claimed that "the greatest genetic structure that exists in the human population occurs at the racial level" (Risch et al. 2002). Our results show that this is not the case, and we see no reason to assume that "races" represent any units of relevance for understanding human genetic history.

In a response to Serre and Pbo (2004), Rosenberg et al. (2005) maintain that their clustering analysis is robust. Additionally, they agree with Serre and Pbo that membership of multiple clusters can be interpreted as evidence for clinality (isolation by distance), though they also comment that this may also be due to admixture between neighbouring groups (small island model). Thirdly they comment that evidence of clusterdness is not evidence for any concepts of "biological race".[27]

Clustering does not particularly correspond to continental divisions. Depending on the parameters given to their analytical program, Rosenberg and Pritchard were able to construct between divisions of between 4 and 20 clusters of the genomes studied, although they excluded analysis with more than 6 clusters from their published article. Probability values for various cluster configurations varied widely, with the single most likely configuration coming with 16 clusters although other 16-cluster configurations had low probabilities. Overall, "there is no clear evidence that K=6 was the best estimate" according to geneticist Deborah Bolnick (2008:76-77).[33] The number of genetic clusters used in the study was arbitrarily chosen. Although the original research used different number of clusters, the published study emphasized six genetic clusters. The number of genetic clusters is determined by the user of the computer software conducting the study. Rosenberg later revealed that his team used pre-conceived numbers of genetic clusters from six to twenty "but did not publish those results because Structure [the computer program used] identified multiple ways to divide the sampled individuals". Dorothy Roberts, a law professor, asserts that "there is nothing in the team's findings that suggests that six clusters represent human population structure better than ten, or fifteen, or twenty."[34] When instructed to find two clusters, the program identified two populations anchored around by Africa and by the Americas. In the case of six clusters, the entirety of Kalesh people, an ethnic group living in Northern Pakistan, was added to the previous five.[29][35]

Commenting on Rosenberg's study, law professor Dorothy Roberts wrote that "the study actually showed that there are many ways to slice the expansive range of human genetic variation.

Sarah A. Tishkoff and colleagues analyzed a global sample consisting of 952 individuals from the HGDP-CEPH survey, 2432 Africans from 113 ethnic groups, 98 African Americans, 21 Yemenites, 432 individuals of Indian descent, and 10 Native Australians. A global STRUCTURE analysis of these individuals examined 1327 polymorphic markers, including of 848 STRs, 476 indels, and 3 SNPs. The authors reported cluster results for K=2 to K=14. Within Africa, six ancestral clusters were inferred through Bayesian analysis, which were closely linked with ethnolinguistic heritage. Bantu populations grouped with other Niger-Congo-speaking populations from West Africa. African Americans largely belonged to this Niger-Congo cluster, but also had significant European ancestry. Nilo-Saharan populations formed their own cluster. Chadic populations clustered with the Nilo-Saharan groups, suggesting that most present-day Chadic speakers originally spoke languages from the Nilo-Saharan family and
later adopted Afro-Asiatic languages. Nilotic populations from the African Great Lakes largely belonged to this Nilo-Saharan cluster too, but also had some Afro-Asiatic influence due to assimilation of Cushitic groups over the last 3,000 years. Khoisan populations formed their own cluster, which grouped closest with the Pygmy cluster. The Cape Coloured showed assignments from the Khoisan, European and other clusters due to the population's mixed heritage. The Hadza and Sandawe populations formed their own cluster. An Afro-Asiatic cluster was also discerned, with the Afro-Asiatic speakers from North Africa and the Horn of Africa forming a contiguous group. Afro-Asiatic speakers in the Great Lakes region largely belonged to this Afro-Asiatic cluster as well, but also had some Bantu and Nilotic influence due to assimilation of adjacent groups over the last 3,000 years. The remaining inferred ancestral clusters were associated with European, Middle Eastern, Oceanian, Indian, Native American and East Asian populations.[36]

Jinchuan Xing and colleagues used an alternate dataset of human genotypes including HapMap samples and their own samples (296 new individuals from 13 populations), for a total of 40 populations distributed roughly evenly across the Earth's land surface. They found that the alternate sampling reduced the FST estimate of inter-population differences from 0.18 to 0.11, suggesting that the higher number may be an artifact of uneven sampling. They conducted a cluster analysis using the ADMIXTURE program and found that "genetic diversity is distributed in a more clinal pattern when more geographically intermediate populations are sampled."[3]

A study by the HUGO Pan-Asian SNP Consortium in 2009 using the similar principal components analysis found that East Asian and South-East Asian populations clustered together, and suggested a common origin for these populations. At the same time they observed a broad discontinuity between this cluster and South Asia, commenting "most of the Indian populations showed evidence of shared ancestry with European populations". It was noted that "genetic ancestry is strongly correlated with linguistic affiliations as well as geography".[37]

Studies of clustering reopened a debate on the scientific reality of race, or lack thereof. In the late 1990s Harvard evolutionary geneticist Richard Lewontin stated that "no justification can be offered for continuing the biological concept of race. (...) Genetic data shows that no matter how racial groups are defined, two people from the same racial group are about as different from each other as two people from any two different racial groups.[38] This view has been affirmed by numerous authors[15][16][18] and the American Association of Physical Anthropologists since.[10] A.W.F. Edwards as well as Rick Kittles and Jeffrey Long have criticized Lewontin's methodology.[10] Edwards also charged that Lewontin made an "unjustified assault on human classification, which he deplored for social reasons".[39] In their 2015 article, Keith Hunley, Graciela Cabana, and Jeffrey Long recalculate the apportionment of human diversity using a more complex model than Lewontin and his successors. They conclude: "In sum, we concur with Lewontins conclusion that Western-based racial classifications have no taxonomic significance, and we hope that this research, which takes into account our current understanding of the structure of human diversity, places his seminal finding on firmer evolutionary footing."[8]

Genetic clustering studies, and particularly the five-cluster result published by Rosenberg's team in 2002, have been interpreted by journalist Nicholas Wade, evolutionary biologist Armand Marie Leroi, and others as demonstrating the biological reality of race.[40][41][42] For Leroi, "Race is merely a shorthand that enables us to speak sensibly, though with no great precision, about genetic rather than cultural or political differences." He states that, "One could sort the world's population into 10, 100, perhaps 1,000 groups," and describes Europeans, Basques, Andaman Islanders, Ibos, and Castillians each as a "race".[42] In response to Leroi's claims, the Social Science Research Council convened a panel of experts to discuss race and genomics online.[43] In their 2002 and 2005 papers, Rosenberg and colleagues disagree that their data implies the biological reality of race.[25][27] Over one hundred senior population geneticists denounced Wade's book A Troublesome Inheritance for misinterpreting their work.[44][45]

In 2006, Lewontin wrote that any genetic study requires some priori concept of race or ethnicity in order to package human genetic diversity into defined, limited number of biological groupings. Informed by geneticist, zoologists have long discarded the concept of race for dividing up groups of non-human animal populations within a species. Defined on varying criteria, in the same species widely varying number of races could be distinguished. Lewontin notes that genetic testing revealed that "because so many of these races turned out to be based on only one or two genes, two animals born in the same litter could belong to different 'races'".[46]

Studies that seek to find genetic clusters are only as informative as the populations they sample. For example, Risch and Burchard relied on two or three local populations from five continents, which together were supposed to represent the entire human race.[29] Another genetic clustering study used three sub-Saharan population groups to represent Africa; Chinese, Japanese, and Cambodian samples for East Asia; Northern European and Northern Italian samples to represent "Caucasians". Entire regions, subcontinents, and landmasses are left out of many studies. Furthermore, social geographical categories such "East Asia" and "Caucasians" were not defined. "A handful of ethnic groups to symbolize an entire continent mimic a basic tenet of racial thinking: that because races are composed of uniform individuals, anyone can represent the whole group" notes Roberts.[29][47][48]

The model of Big Few fails when including overlooked geographical regions such as India. The 2003 study which examined fifty-eight genetic markers found that Indian populations owe their ancestral lineages to Africa, Central Asia, Europe, and southern China.[49][50] Reardon, from Princeton University, asserts that flawed sampling methods are built into many genetic research projects. The Human Genome Diversity Project (HGDP) relied on samples which were assumed to be geographically separate and isolated.[51] The relatively small sample sizes of indigenous populations for the HGDP do not represent the human species' genetic diversity, nor do they portray migrations and mixing population groups which has been happening since prehistoric times. Geographic areas such as the Balkans, the Middle East, North and East Africa, and Spain are seldom included in genetic studies.[29][52] East and North African indigenous populations, for example, are never selected to represent Africa because they do not fit the profile of "black" Africa. The sampled indigenous populations of the HGDP are assumed to be "pure"; the law professor Roberts claims that "their unusual purity is all the more reason they cannot stand in for all the other populations of the world that marked by intermixture from migration, commerce, and conquest."[29]

King and Motulsky, in a 2002 Science article, states that "While the computer-generated findings from all of these studies offer greater insight into the genetic unity and diversity of the human species, as well as its ancient migratory history, none support dividing the species into discrete, genetically determined racial categories".[53] Cavalli-Sforza asserts that classifying clusters as races would be a "futile exercise" because "every level of clustering would determine a different population and there is no biological reason to prefer a particular one". Bamshad, in 2004 paper published in Nature, asserts that a more accurate study of human genetic variation would use an objecti
ve sampling method. An objective sampling method would chose populations randomly and systematically across the world, including those populations which are characterized by historical intermingling, instead of cherry-picking population samples which fit a priori concept of racial classification. Roberts states that "if research collected DNA samples continuously from region to region throughout the world, they would find it impossible to infer neat boundaries between large geographical groups."[29][54][55][56]

Anthropologists such as C. Loring Brace,[57] philosophers Jonathan Kaplan and Rasmus Winther,[58][58][59][60] and geneticist Joseph Graves,[61] have argued that while there it is certainly possible to find biological and genetic variation that corresponds roughly to the groupings normally defined as "continental races", this is true for almost all geographically distinct populations. The cluster structure of the genetic data is therefore dependent on the initial hypotheses of the researcher and the populations sampled. When one samples continental groups the clusters become continental, if one had chosen other sampling patterns the clustering would be different. Weiss and Fullerton have noted that if one sampled only Icelanders, Mayans and Maoris, three distinct clusters would form and all other populations could be described as being clinally composed of admixtures of Maori, Icelandic and Mayan genetic materials.[62] Kaplan and Winther therefore argue that seen in this way both Lewontin and Edwards are right in their arguments. They conclude that while racial groups are characterized by different allele frequencies, this does not mean that racial classification is a natural taxonomy of the human species, because multiple other genetic patterns can be found in human populations that crosscut racial distinctions. Moreover, the genomic data underdetermines whether one wishes to see subdivisions (i.e., splitters) or a continuum (i.e., lumpers). Under Kaplan and Winther's view, racial groupings are objective social constructions (see Mills 1998 [63]) that have conventional biological reality only insofar as the categories are chosen and constructed for pragmatic scientific reasons.

Genetic clustering was also criticized by Penn State anthropologists Kenneth Weiss and Brian Lambert. They asserted that understanding human population structure in terms of discrete genetic clusters misrepresents the path that produced diverse human populations that diverged from shared ancestors in Africa. Ironically, by ignoring the way population history actually works as one process from a common origin rather than as a string of creation events, structure analysis that seems to present variation in Darwinian evolutionary terms is fundamentally non-Darwinian."[64]

Commercial ancestry testing companies, who use genetic clustering data, have been also heavily criticized. Limitations of genetic clustering are intensified when inferred population structure is applied to individual ancestry. The type of statistical analysis conducted by scientists translates poorly into individual ancestry because they are looking at difference in frequencies, not absolute differences between groups. Commercial genetic genealogy companies are guilty of what Pillar Ossorio calls the "tendency to transform statistical claims into categorical ones".[65] Not just individuals of the same local ethnic group, but two siblings may end up beings as members of different continental groups or "races" depending on the alleles they inherit.[29]

Many commercial companies use data from the International HapMap Project (HapMap)'s initial phrase, where population samples were collected from four ethnic groups in the world: Han Chinese, Japanese, Yoruba Nigerian, and Utah residents of Northern European ancestry. If a person has ancestry from a region where the computer program does not have samples, it will compensate with the closest sample that may have nothing to do with the customer's actual ancestry: "Consider a genetic ancestry testing performed on an individual we will call Joe, whose eight great-grandparents were from southern Europe. The HapMap populations are used as references for testing Joe's genetic ancestry. The HapMap's European samples consist of "northern" Europeans. In regions of Joe's genome that vary between northern and southern Europe (such regions might include the lactase gene), the genetic ancestry test is using the HapMap reference population is likely to incorrectly assign the ancestry of that portion of the genome to a non-European population because that genomic region will appear to be more similar to the HapMap's Yoruba or Han Chinese samples than to Northern European samples.[66] Likewise, a person having Western European and Western African ancestries may have ancestors from Western Europe and West Africa, or instead be assigned to East Africa where various ancestries can be found.[67] "Telling customers that they are a composite of several anthropological groupings reinforces three central myths about race: that there are pure races, that each race contains people who are fundamentally the same and fundamentally different from people in other races, and that races can be biologically demarcated." Many companies base their findings on inadequate and unscientific sampling methods. Researchers have never sampled the world's populations in a systematic and random fashion.[29]

Roberts argues against the use of broad geographical or continental groupings: "molecular geneticists routinely refer to African ancestry as if everyone on the continent is more similar to each other than they are to people of other continents, who may be closer both geographically and genetically.[29]Ethiopians have closer genetic affinity with Armenians than with Bantu populations.[68] Similarly, Somalis are genetically more similar to Gulf Arab populations than to other populations in Africa.[69] Braun and Hammonds (2008) asserts that the misperception of continents as natural population groupings is rooted in the assumption that populations are natural, isolated, and static. Populations came to be seen as "bounded units amenable to scientific sampling, analysis, and classification".[70] Human beings are not naturally organized into definable, genetically cohesive populations.

Software which support genetic clustering calculation.

See the original post:
Human genetic clustering - Wikipedia

Prepared for the future – CU Denver Today (press release)

CU Denvers first group of bioengineering undergraduates

We were all in it together

Thats how Jacob Altholz, a recent CU Denver graduate, remembers his experience in the undergraduate bioengineering program, which is part of the College of Engineering and Applied Science with upper division courses taught on CU Anschutz Medical Campus. Jacob and 14 of his classmates are the first group of students to graduate from the program, which is the first of its kind in Colorado.

His fellow classmate, Rachelle Walter, also remembers how much she enjoyed learning how to work together. The program created a cohesive environment that allowed students to work closely with one another and make friendships to last a lifetime.

There were definitely a few late nights and waves of emotion, but we had each other, Walter said. I know something about each of my classmates and I will even be continuing my bioengineering education alongside one of them.

A Colorado native, Altholz had excelled at math and science in high school, so an engineering degree seemed like the right path. He chose bioengineering because of its biological nature and the opportunity to work in a field related to health policy, another area of interest for him. I think of biology as a people-based study and Im a social person, so I like being around other people, he said. The bioengineering program gave him the chance to work with others while also challenging his intellectual skills. Little did he know hed also meet some of his closest friends and be given so many opportunities along the way.

Both Altholz and Walter went through the program while working at the same time, and CU Denver offered them the flexibility to do so. Both found CU Denver to be the perfect atmosphere for students trying to get a degree and start a career at the same time. Walter also enjoyed the diversity of students at CU Denver. With students coming from all over Colorado, CU Denver is the perfect intersection for students of different backgrounds to meet and form friendships, she said.

At the undergraduate level bioengineering offers rigorous training, combining mathematical and physical sciences with engineering principles. At the core of bioengineering is a focus on catalyzing technology to cure and prevent disease.

CU Denver gave us skills that we can sell, Altholz explained. Bioengineering is a relatively new field with big potential for the future, but as Altholz sees it, the degree is meaningless unless you also have skills and experience when you get it. An engineering degree already puts graduates ahead of the game, but in such a rapidly growing field, students need hands-on experience now more than ever. Thats where CU Denver meets the needs of its students head-on.

The CU Denver undergraduate bioengineering program offered research and collaborative opportunities across departments. In fact, Walter had the opportunity to do an American Physiological Society Undergraduate Summer Research Fellowship, where she was published alongside Associate Professor Richard Benninger, PhD, and Post-doctoral Research Fellow Nikki Farnsworth, PhD.

Between working in a prosthetics lab and working in the cardiology department of the Colorado Childrens Hospital, Altholz was able to get hands-on experience through numerous internships, while being connected to faculty and students of other departments along the way. Everything I was doing felt relevant, he said.

By attending CU Denver, Walter and Altholz benefited from new facilities and a program tailored to face the needs of the bioengineering field, as Altholz describes it. Unlike similar degree programs, which start with a mechanical engineering core and add biological components, CU Denvers program was created with bioengineering in mind.

We had the opportunity to learn skills and concepts directly in the context of bioengineering, said Walter. Using CU Denvers resources and keeping the integrative focus of the program in mind, professors brought in guest lecturers and faculty from other departments to create well-rounded courses.

By maintaining a small core group of students, faculty had the opportunity to offer more one-on- one feedback and really get to know the students capabilities. In more than one way, they got to grow up together, leaning on one another when the going got tough, and celebrating one another when they succeeded.

While Walter has decided to continue to get her masters degree in bioengineering, Altholz has decided to begin medical school this fall. Even in this new field, he is staying true to the core of bioengineering the cure and prevention of disease.

Read this article:
Prepared for the future - CU Denver Today (press release)

Lehigh establishes new Department of Bioengineering – The Brown and White

Lehigh has established a new Department of Bioengineering that will build upon the universitys existing bioengineering undergraduate and graduate programs, according to an announcement from Provost Patrick V. Farrell.

The department, which was formally announced on July 1, will be chaired by Professor Anand Jagota, a member of the chemical and biomolecular engineering faculty who has chaired the bioengineering program since 2004.

As Lehigh moves toward the creation of a new College of Health, the new Department of Bioengineering will form an essential connection point for ongoing interdisciplinary research and serve as a natural channel of partnership between the colleges, Farrell wrote.

The initial department faculty includes 17 members with academic appointments, as well as 17 affiliated members, according to the announcement. Their research is supported by, among others, the National Institutes of Health, the National Science Foundation, the U.S. Department of Defense and the U.S. Department of Energy.

The field of bioengineering was born out of a combination of elements from other well-established disciplines, Jagota told University Communications. In recent years, it has developed its own language, its own tools, its own gravitational pull, so to speak. Thus, the timing is right for Lehigh to recognize this evolution by organizing the faculty and students working in this space into a self-standing department.

Visit link:
Lehigh establishes new Department of Bioengineering - The Brown and White

The Latest: Tillerson: Trump, Putin had ‘positive chemistry’ – SFGate

HAMBURG, Germany (AP) The Latest on President Donald Trump's second official visit to Europe (all times local):

8:10 p.m.

Russia's foreign minister says President Donald Trump has accepted Russian President Vladimir Putin's assurances that Moscow didn't meddled in the 2016 U.S. presidential election.

Sergey Lavrov made the claim to reporters following Trump and Putin's lengthy meeting on the sidelines of an international summit in Germany.

That account appears at odds with Secretary of State Rex Tillerson's description of the meeting.

Tillerson said the president was "rightly focused on how do we move forward from what may be simply an intractable disagreement at this point."

U.S. intelligence officials have blamed Russia for election hacking and other efforts to influence the election to help Trump win.

___

President Donald Trump meets with Russian President Vladimir Putin at the G20 Summit, Friday, July 7, 2017, in Hamburg.

President Donald Trump meets with Russian President Vladimir Putin at the G20 Summit, Friday, July 7, 2017, in Hamburg.

President Donald Trump meets with Russian President Vladimir Putin at the G20 Summit, Friday, July 7, 2017, in Hamburg.

President Donald Trump meets with Russian President Vladimir Putin at the G20 Summit, Friday, July 7, 2017, in Hamburg.

The Latest: Russia say Trump accepts Putin's meddling denial

8:02 p.m.

Russia's foreign minister says that Russian military police will monitor a cease-fire in southwestern Syria, per a Russia-U.S. deal.

Sergey Lavrov spoke to reporters after talks between Russian President Vladimir Putin and President Donald Trump in Germany.

He described the lengthy talks as "very constructive" and said they touched on cybersecurity, Ukraine, North Korea and other issues.

Under the cease-fire deal Lavrov says was brokered by Russia, the U.S. and Jordan, Moscow and Washington will ensure the cessation of hostilities and humanitarian access.

A monitoring center will be set up in Jordan, and the Russian military police will oversee its implementation

___

7:55 p.m.

Leaders of the Group of 20 economic powers and their spouses have gathered at Hamburg's spectacular new Elbphilharmonie concert hall.

President Donald Trump and first lady Melania Trump were seated next to French President Emmanuel Macron and his wife, Brigitte.

The leaders applauded the summit host, German Chancellor Angela Merkel, as she took her place in the row behind the Trumps.

The leaders are hearing Beethoven's Ninth Symphony, conducted by American Kent Nagano.

Merkel and her husband, Joachim Sauer, are classical music fans. Sauer, who rarely accompanies the chancellor on official business, was on hand for the G-20 and to host the concert alongside Merkel.

___

7:53 p.m.

Secretary of State Rex Tillerson says President Donald Trump and Russian President Vladimir Putin had "positive chemistry" during their first meeting.

Trump and Putin met for more than two hours Friday at an international summit in Germany. It was only scheduled to last 30 minutes.

Tillerson said the meeting was "very constructive." He added that "there was so much to talk about" that neither leader "wanted to stop."

The top U.S. diplomat also said that First Lady Melania Trump was sent into the meeting at one point to "see if she could get us out of there "

But Tillerson said the meeting lasted another hour after the visit, joking that "clearly she failed."

___

7:45 p.m.

The Russians have asked the U.S. for proof and evidence of their alleged interference in the 2016 election, which Russia denies.

Secretary of State Rex Tillerson says the ask was made during a lengthy meeting in Germany between President Donald Trump and Russian President Vladimir Putin.

Tillerson said the president pressed Putin on the issue and that they'd agreed to follow-up meetings.

That includes a new working group on cybersecurity and election interference.

Tillerson says, "the meeting was very constructive" and that the two leaders "connected very quickly."

___

7:44 p.m.

Secretary of State Rex Tillerson says that President Donald Trump and Russian President Vladimir Putin "had a pretty good exchange" as to how to handle the threat of North Korea.

But Tillerson added Friday after the leaders' meeting that the Russians "see it a little different than we do."

The top U.S. diplomat noted that Russia's ultimate goal mirrors what the United States wants: the denuclearization of the Korean peninsula.

He said the differences are the tactics used to achieve that goal. He did not elaborate.

Tillerson also said that, despite Trump's recent tweet to the contrary, the U.S. has not "given up hope" that China will help with North Korea.

Trump and Putin met for more than two hours at an international summit in Germany.

___

7:35 p.m.

Secretary of State Rex Tillerson says the Trump administration sees no long-term role for the Assad family and the Assad regime in Syria.

Tillerson tells reporters at a briefing in Hamburg, Germany that "how" Syrian President Bashar Assad "leaves is yet to be determined." But he says he thinks there will be a transition away from the Assad government.

The United States and Russia announced an agreement Friday for a cease-fire in southwest Syria set to take effect July 9.

Tillerson describes the deal as the first indication of the Trump administration and Russia being able to work together in Syria.

___

7:27 p.m.

President Donald Trump opened his meeting with Russian President Vladimir Putin by raising concerns about Russian interference in the 2016 presidential election.

Secretary of State Rex Tillerson tells reporters that Trump pressed Putin on the issue during their more than two-hour meeting on the sidelines of a summit of world leaders in Germany.

Tillerson says Putin denied any involvement during his more than two-hour meeting with Trump.

Tillerson says he thinks the president "is rightly focused on how do we move forward from something that may be an intractable disagreement at this point."

____

7:10 p.m.

Russian President Vladimir Putin says he had a long conversation with President Donald Trump, and says that "many issues have piled up, including Ukraine, Syria, some bilateral and other issues."

He says he and Trump also spoke about "fighting terrorism and cybersecurity" during their two-plus-hour meeting

Putin made the comments at the beginning of a meeting with Japanese Prime Minister Shinzo Abe. He offered apologies to Abe for running late after his meeting with Trump stretched far longer than originally scheduled.

____

6:32 p.m.

Donald Trump and Vladimir Putin spent more than two hours meeting Friday on the sidelines of a world leaders' summit.

State Department spokesman RC Hammond says that the meeting in Hamburg, Germany lasted two hours and 16 minutes.

It had originally been scheduled for just 30 minutes.

____

6:15 p.m.

A meeting between Presidents Donald Trump and Russian President Vladimir Putin that was supposed to last a half-hour has stretched to more than 90 minutes.

Trump had originally been scheduled to depart the meeting site of the Group of 20 world leaders in Hamburg, Germany at 4:20 p.m. local time following his meeting with Putin.

But Svetlana Lukash, a Russian official accompanying Putin at the talks, said the meeting that began around 4 p.m. local time was still ongoing at 5:50 p.m.

The longer-than-scheduled meeting comes as US. officials say the United States and Russia have reached an agreement for a cease-fire in southwest Syria that is set to take effect on Sunday.

____

5:44 p
.m.

Hillary Clinton's former campaign chair is telling President Donald Trump to "Get a grip" and get his "head in the game."

John Podesta says on Twitter: "Dude, get your head in the game. You're representing the US at the G20."

Trump had tweeted earlier Friday that "Everyone" in Hamburg, Germany "is talking about why John Podesta refused to give the DNC server to the FBI and the CIA. Disgraceful!"

Trump is attending a summit of world leaders in the country.

Podesta said he saw Trump's tweet during a stop on a cross-country road trip with his wife.

He says, "God only knows what you'll be raving about on twitter by the time we get to Utah."

____

5:05 p.m.

President Donald Trump emphasized the importance of renegotiating a longstanding continental trade agreement in a meeting with his Mexican counterpart.

The White House said in a statement Friday that Trump and President Enrique Pena Nieto discussed ways "to help workers in both countries" as part of the renegotiation of the North American Free Trade Agreement.

The statement says the leaders also discussed regional challenges, including drug trafficking, illegal migration, and the crisis in Venezuela. It does not say whether they discussed Trump's proposed U.S.-Mexican border wall.

A readout from the Mexican government said the two men underscored "the importance of modernizing" NAFTA in a way that "results in tangible benefits for the economies and societies of North America."

Trump and Pena Nieto met on the sidelines of the G-20 summit in Hamburg, Germany.

___

5:02 p.m.

President Donald Trump's oldest son is complaining about the loud camera clicks that made it hard to hear his father and Russian president Vladimir Putin's brief remarks to the press ahead of their highly-anticipated meeting.

Donald Trump Jr. asks on Twitter: "With all the Cameras clicking away rapid fire you can't actually hear what they're saying? How many pictures do you need of the same scene?"

Professional news photographers typically take dozens or hundreds of shots of the same event to capture a variety of angles and facial expressions.

Trump and Putin are meeting at the Group of 20 world leaders' summit in Germany.

Reporters and photojournalists were allowed in the room for about two minutes to capture the scene.

Trump's son is a frequent critic of the press.

Read more:
The Latest: Tillerson: Trump, Putin had 'positive chemistry' - SFGate

1 Injured in Chemical Reaction at University of Maryland Chemistry … – NBC4 Washington

WATCH LIVE

One person was injured Thursday afternoon during an adverse chemical reaction in a chemistry lab at the University of Maryland College Park.

The victim sustained injuries to the facial area, and was decontaminated and taken to a hospital for treatment, Prince George's Fire spokesman Mark Brady posted on Twitter.

Prince George's Fire is investigating the reaction, which Brady described as small, at the university's chemistry building.

A Prince George's Fire hazmat team is on the scene at 8501 Regents Drive, assisting UMd. Physical Plant and Chemistry officials with evaluation and cleanup, Brady said.

The chemistry building was evacuated shortly after the incident, and Regents Drive between Field House Drive and Stadium Drive was closed to traffic, according to the UMd. Police Department. The building and street have since reopened.

Published at 3:11 PM EDT on Jul 6, 2017 | Updated at 4:29 PM EDT on Jul 6, 2017

See the article here:
1 Injured in Chemical Reaction at University of Maryland Chemistry ... - NBC4 Washington

The Anatomy of a Super Strat – Reverb News

The term Super Strat has been used loosely to describe a whole array of electric guitars with a doublecutaway, Fender Stratocasterstyle body, smokin hot humbuckers, and a locking tremolo system.

The trend was kicked off by Eddie Van Halen with his homebrew Frankenstrat, which inspired a rich tradition of amateurbuilt Super Strats. The Super Strat craze was born thanks in large part to these amateurs modding lackluster guitars built by the big manufacturers.

In the late 1970s and early 1980s, Fender and Gibson were growing out of touch with their market largely due to corporate mismanagement. CBS, for instance, was tainting Fender's established legacy as a highquality brand by prioritizing cost cuts over consumer demands. Unstable 3bolt necks were introduced and players were not happy.

Likewise, Gibson (owned by the Norlin company) was cutting costs by building inferior guitars with heavy, multipiece bodies. The Norlin eras ugly designs didnt help the companys case (check out the Corvus).

During the this time, companies such as Schecter, Warmoth, and Mighty Mite were offering replacement bodies for sale by mail order. Until then, only professional luthiers had easy access to replacement parts.

These companies gave the lay shredder and home tinkerer the ability build a guitar for the first time. This is how Eddie Van Halen became the prototypical amateur guitar modifier.

Of course, there is a massive amount of diversity amongst those manufacturers as part of a Super Strat arms race in the 80s, but some common tropes did emerge.

Literally going part by part to trace which builders were responsible for which innovations unfolds a fascinating tale about one of the few guitars that was not designed by one company and copied over and over like the Les Paul, for example but was truly designed by an entire industry.

Many guitar players were embracing heavy woods and hardware in a bid for better tone. Heavy body woods offered by amateurfocused companies like Warmouth and Schechter included padauk, zebrawood, and wenge, as well as heavier variants of the more commonly used maple and ash.

The advent of highergain amps, preamps, rack effects, and new pedal designs needed a more focused and direct guitar sound, and the heavier wood guitars helped create a more uniform tone.

On the other end of the spectrum, some modobsessed players wanted to go as light as possible and turned to poplar and basswood two woods that are now commonly used in guitar manufacturing.

ESP LTD Alex Wade AW-7, Padouk

Ibanez RG752 RG Prestige Series, Wenge

ESP LTD M-100 FM M-Series, Basswood

The neck joint on the original generation of Super Strats was almost exclusively a classic 4bolt neck plate design. This was more stable than the 3bolt design Fender was using in the late 70s and 80s, which led to the necks shifting and causing playability problems. In fact, many players at the time converted their 3bolt Fender to a 4bolt for better stability.

Yet two of the most important neck innovations at this time were the advent of the thinner neck and the widespread adoption of neckthrough construction.

Jackson Pro Soloist SL2Q

With the rise of fast metal playing and guitar virtuosity by the likes of Eddie Van Halen and Steve Vai, players at the time were seeking better and better playability. Thats when necks began to become thinner and wider, with Ibanez, Kramer, and Jackson leading the pack.

Ibanez also pioneered neckthrough guitars for the masses with its Alembicinspired musician models, and Grover Jackson made this a Super Strat innovation in its own right.

When working with Charvel, luthier Grover Jackson tweaked the Super Strat template through oneoff custom guitars he built as side projects. Those neckthrough projects would be refined into the Soloist, which Jackson would use to launch his eponymous guitar brand.

Neckthrough construction allowed for a more responsive guitar with much greater sustain. This method of construction also allowed for a greatly reduced heel, making access to the higher frets effortless. Shredders were no longer impeded by a bulky heel of a traditional bolton or set neck guitar.

Without a doubt, the iconic bridge of the Super Strat is the Floyd Rose locking tremolo system. While many have tried their hands at the double locking tremolo design game, only Floyd has become an industry standard.

Others have had limited or no success, such as the Kahler, Washburn Wonderbar, Kramer Rockinger, and various less precise variations. None have achieved the reliability of the Floyd.

Jackson Pro Soloist SL2Q with a Floyd Rose

Designing in 1977, Floyd Rose found that tuning stability was only achieved when the string was locked at the neck and at the bridge. With this doublelocking system, the string would no longer slip at the nut or the saddle of the bridge.

This doublelocking innovation not only contributed much needed tuning stability to a tremolo system, but also allowed for wild pitchshifting down and up. The range of that pitch shifting was more dynamic than ever, especially when pulling the bar to pitch the notes up. The Floyd Rose system became a tool that every burgeoning guitar player needed to master.

Floyd also pioneered the use of fine tuners at the bridge to really keep the guitar in playable and precise tuning. Kramer was the first manufacturer to adopt the Floyd Rose system, ditching the Rockinger system that was originally favored by Van Halen for his signature model.

Van Halen and Rose worked together on many of the systems refinements, and it has remained relatively unchanged and unchallenged since getting just about nailed in the mid1980s.

Fender Yngwie Malmsteen Brass Nut

Modders in the 1970s and 1980s were experimenting with heavy materials to induce more sustain. In the rare occasion that a Super Strat did not have a locking nut, brass was the ideal nut material.

Ibanez became the first manufacturer to popularize the brass nut, even though Gretsch had used the material on and off in the 1950s and Alembic started using it for smallerscale builds in the 1970s.

Jazz players such as George Benson (also an Ibanez endorser) used combination bone and brass nuts to get the best of both worlds. Many players found brass's long sustain worthwhile despite the inconvenience of strings breaking more often at the nut.

Pickups are the biggest tonal driver in the Super Strat. With the boom of companies building replacement pickups in the 1970s and 1980s including Dimarzio, Seymour Duncan, and Schecter the home modder had more options than ever for cultivating a signature sound.

Kramer Baretta 1985 Reissue

For the Super Strat, higher output humbuckers were preferred, since they made overdriving an amp a whole lot easier. Ceramic magnets were used over alnico since they created higher output, lending pickups a more powerful and focused sound. Popular ceramic models included the Seymour Duncan JB, Dimarzio Super Distortion, and the EMG 81.

Ceramic magnets can be harsh, but that harshness can be tamed through some creative design. A pickups positioning, for instance, is one of the most interesting influencers on tone.

Many Super Strat manufacturers angled their bridge humbucker like Kramer with its Baretta to better align the pole pieces with the string spacing of the Floyd trem.

This shifting emphasizes more bass and higher treble while limiting the flubby and harsh bass tones that bridge humbuckers on Stratstyle guitars can sometimes have.

You cant talk about the Super Strat without talking about the wild finishes and graphic art so many of these models exhibited. Starting with Van Halens Frankestrat, Super Strat players prided themselves on the individuality of their guitars.

Ibanez, Charvel, Hamer, and the many Japanese imports of the time (Aria, Westone, etc.) pioneered the unique solid colors, while Kramer and Jack
son went over and above anything seen at the time.

Kramer had tiger, leopard, and other animal print color schemes, while Jackson had amazing graphics, with the samurai, lava, piles of skulls, and scantily clad women being popular themes. This movement toward art being a fundamental part of the instrument pushed figured wood to the background of guitar aesthetics.

Kramer Pacer, Tiger Stripe

Jackson USA DK1 Dinky, Skull

Ibanez Steve Vai JEM777, Loch Ness Green

When playing a classic Super Strat, it can sound harsh, heavy, and bright. However, these guitars come alive with heavy distortion.

The concentrated bright tone allows for the guitar to cut through a highgain amp. When played clean with delay, chorus, and reverb, the brightness keeps the guitar from getting bogged down by the lowend those effects tend to add.

While the Super Strat is very much so a relic of the 80s, nothing is better for highgain, highspeed, and deepdive tremolo playing.

Who made your favorite Super Strat? Ever made one for yourself? Let us know in the comments.

The rest is here:
The Anatomy of a Super Strat - Reverb News

The ‘Rick And Morty: Anatomy Park’ Board Game Is Almost Here – Konbini US

Can't stand to wait another two weeks for the release of Rick and Morty season 3? In that case, create your own wacky adventure by getting the Rick and Morty: Anatomy Park board game.

That's right, of all the disgusting, crazy and bonkers adventures the mad scientist and his grandson have gone through, you can now relive the season 1 episode that sees the duo venture into a microscopic theme park built inside Ruben, the homeless Santa.

(Image: Konbini)

As you've probably guessed, the goal of the game is to successfully build a theme park inside the human body. Just like the characters in the series, you'll have to face many diseases and bodily reactions to win.

However, since it's a Rick and Morty-themed game, there's a catch! If someone pulls a "Bodily Reaction" card, the holder will actually have to act out its actions. Each player will get to choose between Rick, Morty, Annie, Poncho, Roger and park operator Dr. Xenon Bloomone, all of which featured in the episode.

The game itself will feature all you need to spend a gruesome, yet hilarious evening:

46 park tiles;Nine focus group tiles;14 bodily reactions cards;Three dice;Six oversized character cards;Six character standees;Six disease standees;Six Master Plan cards;30 control cubes;Lots of Victory Points tokens;Rulebook.

Lead designer Matty Hyra announced the game will also include exclusive attractions that did not feature in the original episode. As long as "Pirates of the Pancreas" and the friendly Hepatitis C are there, it'll be a hit for sure.

Rick and Morty: Anatomy Park comes out on July 12 and is expected to cost $30.

ReadMore ->Microsoft Put The Entire First Season Of 'Dragon Ball Z' Online For Free

I like watching films and going to music festivals. Get in touch at aurelien.huet@konbini.com

Read more here:
The 'Rick And Morty: Anatomy Park' Board Game Is Almost Here - Konbini US

Remember The ‘Anatomy Park’ Episode Of Rick And Morty? Now You Can Act It Out In Real Life – moviepilot.com

If you've ever watched Rick and Morty in one of their absolutely bonkers adventures and then gone on to say to yourself, "I'd love to do that!" well, my friend, your dream can now come true. I'd hold off on imagining yourself getting a jetpack or being inside Rick's UFO to fly into the cosmos, thoughwe're probably still a few decades away from that. But don't worry, we have the next best thing.

#CartoonNetwork Enterprise has partnered with Cryptozoic Entertainment to bring us #RickAndMortyAnatomyPark, a board game based on one of the duo's most disgusting adventures: 'Anatomy Park.' In the Season 1 episode, the grandson-granddad duo, alongside other companions, venture into a microscopic theme park built inside a homeless man. It was hilarious and horrifying. It was...hilarifying.

The end goal of the game is to successfully build a theme park inside the human body, and the approach to its rules is pretty original and a great representation of the craziness that is #RickAndMorty's trademark. To build the different attractions, players will have to work their way through bodily reactions and diseases, and they have a real-life effect. If someone pulls a "Bodily Reaction" card, for example, the holder will have to act out its actions.

Who will fans be able to embody (uh...literally) on this insane journey? Players will be able to choose between Rick, Morty, Annie, the treacherous Poncho, Roger and the iTunes gift card-giver himself, Dr. Xenon Bloom. Unfortunately, none of Morty's family members will be able to join in on the fun, which is understandable since they didn't go into the theme park in the episode. Although... now that I think about it, Rick wasn't inside the body, eitherhe just threw it into space and blew it up (I know, that's the show)... But you know what? I won't try to make sense of the series' logic.

The game will be packed with content to make your experience inside the homeless Santa Claus as realistic and gruesome as possible. Here are all the goodies that will make that happen:

Going by the 'Anatomy Park' episode (and having a general understanding of the kind of gruesome things Rick and Morty go through on a daily basis) I have a pretty good idea of what we can expect from the diseases. But I'll be happy just as long as there's a giant Hepatitis C beast in there to somehow defend us from other monsters.

According to the game's lead designer, Matty Hyra, the game will include some new attractions not seen in the original episode, designed by Robb Mommaerts. "When can I get this sci-fi masterpiece," you ask? You'll be able to do it on July 12. Meanwhile, #RickandMortySeason3 will return on Adult Swim on July 30, 2017.

Will you be playing Rick And Morty: Anatomy Park once it comes out? Let me know in the comments!

See the original post:
Remember The 'Anatomy Park' Episode Of Rick And Morty? Now You Can Act It Out In Real Life - moviepilot.com

IARPA seeks tech to ID bioengineered life forms – FCW.com (blog)

IARPA seeks tech to ID bioengineered life forms

WHAT: A new bio-detection tech development effort to help defend against human engineered biological threats.

WHY: With advances in genetic engineering and gene editing, the intelligence community is concerned about possible threats from chimerical life forms.

The research arm of the intelligence community is hoping new bio-detection technology can be developed to help defend against human engineered biological threats.

That idea might sound a bit familiar to science fiction buffs.

It is reminiscent of the science fiction film "Blade Runner," an adaptation of Philp K. Dicks classic 1968 novel "Do Androids Dream of Electric Sheep?" In the story, special futuristic cops are charged with defending human civilization from the depredations of genetically engineered android super-soldiers dubbed replicants.

In a June 19 announcement, the Intelligence Advanced Research Projects Activity said it is looking for technology that can detect human engineered changes to natural biological systems.

Emerging genetic editing tools have the potential to aid in the development of new vaccines and pharmaceuticals and to create hardy strains of crops. However, in the wrong hands, these tools could also be used to warp organisms into deliberate weapons or be misused in ways that could "accidentally or deliberately" threaten national health, security or the economy, according to the solicitation.

IARPA said its Finding Engineering-Linked Indicators (FELIX) program looks to develop new tech that can spot genetically engineered changes within biological systems to spur "mitigation responses to unlawful or accidental release of organisms." IARPA said it wants to develop a suite of tools to detect a range of engineered bio-organisms from viruses, bacteria, insects, animals and plants that have been developed from natural organisms "that are either purposefully or accidentally developed and/or released with the potential to cause harm."

IARPA plans a proposers' day on July 27 before it sends out a formal solicitation for the technology.

IARPA said technologies it wants to discuss include novel methods and high throughput techniques in genomics, systems biology, bioinformatics and evolutionary biology.

The tools it's aiming to develop could find genetic signatures that haven't been accessible before with previous technologies, using data from multiple interrogation points, increasing sensitivity, improving the quality of the data and leveraging technologies that can increase throughput and reduce the complexity of sample analysis.

IARPA said it envisions FELIX development as a two-phase program. The first phase, it said, is to develop platforms and technologies that can be made general enough to detect "signatures" that would give away engineered biological systems and develop modeling and analysis of those indicators.

The second phase, IARPA said, will optimize the platform, analysis tools and technologies to detect increasingly complex and sophisticated changes in biological systems and find those engineered changes in a variety of organisms and sample types.

Click here to read the full announcement.

Posted by Mark Rockwell on Jul 05, 2017 at 12:33 PM

See original here:
IARPA seeks tech to ID bioengineered life forms - FCW.com (blog)

How to build a human cell atlas – Nature.com

Casey Atkins for Nature

Aviv Regev likes to work at the edge of what is possible. In 2011, the computational biologist was collaborating with molecular geneticist Joshua Levin to test a handful of methods for sequencing RNA. The scientists were aiming to push the technologies to the brink of failure and see which performed the best. They processed samples with degraded RNA or vanishingly small amounts of the molecule. Eventually, Levin pointed out that they were sequencing less RNA than appears in a single cell.

To Regev, that sounded like an opportunity. The cell is the basic unit of life and she had long been looking for ways to explore how complex networks of genes operate in individual cells, how those networks can differ and, ultimately, how diverse cell populations work together. The answers to such questions would reveal, in essence, how complex organisms such as humans are built. So, we're like, 'OK, time to give it a try', she says. Regev and Levin, who both work at the Broad Institute of MIT and Harvard in Cambridge, Massachusetts, sequenced the RNA of 18 seemingly identical immune cells from mouse bone marrow, and found that some produced starkly different patterns of gene expression from the rest1. They were acting like two different cell subtypes.

That made Regev want to push even further: to use single-cell sequencing to understand how many different cell types there are in the human body, where they reside and what they do. Her lab has gone from looking at 18 cells at a time to sequencing RNA from hundreds of thousands and combining single-cell analyses with genome editing to see what happens when key regulatory genes are shut down.

The results are already widening the spectrum of known cell types identifying, for example, two new forms of retinal neuron2 and Regev is eager to find more. In late 2016, she helped to launch the International Human Cell Atlas, an ambitious effort to classify and map all of the estimated 37 trillion cells in the human body (see 'To build an atlas'). It is part of a growing interest in characterizing individual cells in many different ways, says Mathias Uhln, a microbiologist at the Royal Institute of Technology in Stockholm: I actually think it's one of the most important life-science projects in history, probably more important than the human genome.

Such broad involvement in ambitious projects is the norm for Regev, says Dana Pe'er, a computational biologist at Memorial Sloan Kettering Cancer Center in New York City, who has known Regev for 18 years. One of the things that makes Aviv special is her enormous bandwidth. I've never met a scientist who thinks so deeply and so innovatively on so many things.

When Regev was an undergraduate at Tel Aviv University in Israel, students had to pick a subject before beginning their studies. But she didn't want to decide. Too many things were interesting, she says. Instead, she chose an advanced interdisciplinary programme that would let her look at lots of subjects and skip a bachelor's degree, going straight to a master's.

A turning point in her undergraduate years came under the tutelage of evolutionary biologist Eva Jablonka. Jablonka has pushed a controversial view of evolution that involves epigenetic inheritance, and Regev says she admired her courage and integrity in the face of criticism. There are many easy paths that you can take, and it's always impressive to see people who choose alternative roads.

Jablonka's class involved solving complicated genetics problems, which Regev loved. She was drawn to the way in which genetics relies on abstract reasoning to reach fundamental scientific conclusions. I got hooked on biology very deeply as a result, she says. Genes became fascinating, but more so how they work with each other. And the first vehicle in which they work with each other is the cell.

Regev did a PhD in computational biology under Ehud Shapiro from the Weizmann Institute of Science in Rehovot, Israel. In 2003 she moved to Harvard University's Bauer Center for Genomics Research in Cambridge, through a unique programme that allows researchers to leapfrog the traditional postdoctoral fellowship and start their own lab. I had my own small group and was completely independent, she says. That allowed her to define her own research questions, and she focused on picking apart genetic networks by looking at the RNA molecules produced by genes in cells. In 2004, she applied this technique to tumours and found gene-expression patterns that were shared across wildly different types of cancer, as well as some that were more specific, such as a group of genes related to growth inhibition that is suppressed in acute lymphoblastic leukaemias3. By 2006, at the age of 35, she had established her lab at the Broad Institute and the Massachusetts Institute of Technology in Cambridge.

At Broad, Regev continued working on how to tease complex information out of RNA sequencing data. In 2009, she published a paper on a type of mouse immune cell called dendritic cells, revealing the gene networks that control how they respond to pathogens4. In 2011, she developed a method that could assemble a complete transcriptome5 all the RNA being transcribed from the genes in a sample without using a reference genome, important when an organism's genome has not been sequenced in any great depth.

It was around this time that Levin mentioned the prospect of sequencing the RNA inside a single cell. Up to that point, single-cell genomics had been almost impossible, because techniques weren't sensitive enough to detect the tiny amount of RNA or DNA inside just one cell. But that began to change around 2011.

The study with the 18 immune cells also dendritic cells was meant to test the method. I had kind of insisted that we do an experiment to prove that when we put the same cell types in, everything comes out the same, says Rahul Satija, Regev's postdoc at the time, who is now at the New York Genome Center in New York City. Instead, he found two very different groups of cell subtypes. Even within one of the groups, individual cells varied surprisingly in their expression of regulatory and immune genes. We saw so much in this one little snapshot, Regev recalls.

I think even right then, Aviv knew, says Satija. When we saw those results, they pointed the way forward to where all this was going to go. They could use the diversity revealed by single-cell genomics to uncover the true range of cell types in an organism, and find out how they were interacting with each other.

In standard genetic sequencing, DNA or RNA is extracted from a blend of many cells to produce an average read-out for the entire population. Regev compares this approach to a fruit smoothie. The colour and taste hint at what is in it, but a single blueberry, or even a dozen, can be easily masked by a carton of strawberries.

By contrast, single-cell-resolved data is like a fruit salad, Regev says. You can distinguish your blueberries from your blackberries from your raspberries from your pineapples and so on. That promised to expose a range of overlooked cellular variation. Using single-cell genomics to sequence a tumour, biologists could determine which genes were being expressed by malignant cells, which by non-malignant cells and which by blood vessels or immune cells potentially pointing to better ways to attack the cancer.

The technique holds promise for drug development in many diseases. Knowing which genes a potential drug affects is more useful if there's a way to comprehensively check which cells are actively expressing the gene.

Regev was not the only one becoming enamoured with single-cell analyses on a grand scale. Since at least 2012, scientists have been toying with the idea of mapping all human cell types using these techniques. The idea independently arose in several areas of the world at the same time, says Stephen Quake, a bioengineer at Stanford University in California who co-leads the Chan Zuckerberg Biohub. The Biohub, which
has been funding various biomedical research projects since September 2016, includes its own cell-atlas project.

Around 2014, Regev started giving talks and workshops on cell mapping. Sarah Teichmann, head of cellular genetics at the Wellcome Trust Sanger Institute in Hinxton, UK, heard about Regev's interest and last year asked her whether she would like to collaborate on building an international human cell atlas project. It would include not just genomics researchers, but also experts in the physiology of various tissues and organ systems.

I would get stressed out of this world, but she doesn't.

Regev leapt at the chance, and she and Teichmann are now co-leaders of the Human Cell Atlas. The idea is to sequence the RNA of every kind of cell in the body, to use those gene-expression profiles to classify cells into types and identify new ones, and to map how all those cells and their molecules are spatially organized.

The project also aims to discover and characterize all the possible cell states in the human body mature and immature, exhausted and fully functioning which will require much more sequencing. Scientists have assumed that there are about 300 major cell types, but Regev suspects that there are many more states and subtypes to explore. The retina alone seems to contain more than 100 subtypes of neuron, Regev says. Currently, consortium members whose labs are already working on immune cells, liver and tumours are coming together to coordinate efforts on these tissues and organs. This is really early days, says Teichmann.

In co-coordinating the Human Cell Atlas project, Regev has wrangled a committee of 28 people from 5 continents and helped to organize meetings for more than 500 scientists. I would get stressed out of this world, but she doesn't, Jablonka says. It's fun to have a vision that's shared with others, Regev says, simply.

It has been unclear how the project would find funding for all its ambitions. But in June, the Chan Zuckerberg Initiative the philanthropic organization in Palo Alto, California, that funds the Biohub contributed an undisclosed amount of money and software-engineering support to the Human Cell Atlas data platform, which will be used to store, analyse and browse project data. Teichmann sees the need for data curation as a key reason to focus on a large, centralized effort instead of many smaller ones. The computational part is at the heart of the project, she says. Uniform data processing, data browsing and so on: that's a clear benefit.

In April, the Chan Zuckerberg Initiative had also accepted applications for one-year pilot projects to test and develop technologies and experimental procedures for the Human Cell Atlas; it is expected to announce which projects it has selected for funding some time soon. The applications were open to everyone, not just scientists who have participated in planning meetings.

Some scientists worry that the atlas will drain both funding and effort from other creative endeavours a critique aimed at many such international big-science projects. There's this tension, says Atray Dixit, a PhD student in Regev's lab. We know they're going to give us something, and they're kind of low-risk in that sense. But they're really expensive. How do we balance that?

Developmental biologist Azim Surani at the University of Cambridge, UK, is not sure that the project will adeptly balance quantity and depth of information. With the Human Cell Atlas, you would have a broad picture rather than a deeper understanding of what the different cell types are and the relationships between them, he says. What is the pain-to-gain ratio here?

Surani also wonders whether single-cell genomics is ready to converge on one big project. Has the technology reached maturity so that you're making the best use of it? he asks. For example, tissue desegregation extracting single cells from tissue without getting a biased sample or damaging the RNA inside is still very difficult, and it might be better for the field, some say, if many groups were to go off in their own directions to find the best solution to this and other technical challenges.

And there are concerns that the project is practically limitless in scope. The definition of a cell type is not very clear, says Uhln, who is director of the Human Protein Atlas an effort to catalogue proteins in normal and cancerous human cells that has been running since 2003. There may be a nearly infinite number of cell types to characterize. Uhln says that the Human Cell Atlas is important and exciting, but adds: We need to be very clear, what is the endpoint?

Regev argues that completion is not the only goal. It's modular: you can break this to pieces, she says. Even if you solve a part of a problem, it's still a meaningful solution. Even if the project just catalogues all the cells in the retina, for example, that's still useful for drug development, she argues. It lends itself to something that can unfold over time.

Regev's focus on the Human Cell Atlas has not distracted her from her more detailed studies of specific cell types. Last December, her group was one of three to publish papers6, 7, 8 in which they used the precision gene-editing tool CRISPRCas9 to turn off transcription factors and other regulatory genes in large batches of cells, and then used single-cell RNA sequencing to observe the effects. Regev's lab calls its technique Perturb-seq6.

The aim is to unpick genetic pathways very precisely, on a much larger scale than has been possible before, by switching off one or more genes in each cell, then assaying how they influence every other gene. This was possible before, for a handful of genes at a time, but Perturb-seq can work on 1,000 or even 10,000 genes at once. The results can reveal how genes regulate each other; they can also show the combined effects of activating or deactivating multiple genes at once, which can't be predicted from each of the genes alone.

Dixit, a co-first author on the paper, says Regev is indefatigable. She held daily project meetings at 6 a.m. in the weeks leading up to the submission. I put in this joke sentence at the end of the supplementary methods a bunch of alliteration just to see if anyone would read that far. She found it, Dixit says. It was 3 a.m. the night before we submitted.

Regev's intensity and focus is accompanied by relentless positivity. I'm one of the fortunate people who love what they do, she says. And she still loves cells. No matter how you look at them, they're just absolutely amazing things.

Read the original:
How to build a human cell atlas - Nature.com

After decades of work, Americans may soon be eating genetically engineered salmon – PRI

On a hill above the cold waters around Prince Edward Island, technicians painstakingly create fertilized Atlantic salmon eggs that include growth-enhancing DNA from two other fish species. The eggs will be shipped to tanks in the high rainforest of Panama, where they will produce fish that mature far more quickly than normal farmed salmon.

More than 20 years after first seeking approval from the USFood and Drug Administration, AquaBounty Technologies of Maynard, Massachusetts, plans to bring these AquAdvantage fish to the USand Canadian markets next year. And in the small village of Albany, Indiana, workers will soon begin converting a land-based aquaculture facility to produce about 1,300 UStonsof these salmon annually, in the first USfacility to generate GE animals for human consumption.

The company also plans to open a second aquaculture facility at Prince Edward Island if it can can rise above its latest round of legal battles and persuade grocery stores and restaurants to snap up the genetically engineered fish.

Before the FDA cleared the salmon for consumption in 2015, in its first approval of GE animal protein as human food, it received 1.8 million messages opposing these fish. Perhaps more substantively, many outside researchers remain concerned about AquaBountys plans.

Aquaculture specialists generally arent skeptical about whether the fish will be healthy to eat, although thats one issue hinted at in a lawsuit multiple organizations, including Friends of the Earth, have filed against the FDA.

Dana Perls, senior food and technology campaigner with Friends of the Earth in Berkeley, California, says the FDA didnt fully examine questions about eating the salmon initially raised by Health Canada, that countrys public health department including susceptibility to disease and potential allergic reactions.

This is a poorly studied, risky and unlabeled genetically engineered fish, she says, adding that more than 80 USgrocery chains havecommitted not to buy it.

However, Health Canada eventually concluded that fillets derived from AquAdvantage salmon are as safe and nutritious as fillets from current available farmed Atlantic salmon, and approved the fish for consumption in 2016.

Theres no reason to suspect these fish from a food safety perspective, says Cyr Couturier, chair of aquaculture programs at Memorial Universitys Marine Institute in St. Johns, Newfoundland. They have no unnatural products that humans wouldnt otherwise consume.

Similar transgenic salmon created by a decades-long Fisheries and Oceans Canada research program tested well within normal salmon variations, adds Robert Devlin, engineering research scientist at the agency in North Vancouver, British Columbia.

But critics do raise two other main concerns about AquaBountys quest: the economic sustainability of the land-based approach, and the environmental risk to ecosystems if the fish escape.

AquaBounty will raise its GE fish in land-based recirculating aquaculture systems, known as RAS basically huge aquaria designed to minimize water use, maximize resources and accommodate high stocking densities.

While farming salmon in sea cages is less expensive and less technologically complex than a land-based farm, the companys website points out, sea cages are susceptible to a number of hazards such as violent storms, predators, harmful algal blooms, jellyfish attacks, fish escapes, and the transmission of pathogens and parasites from wild fish populations.

Given the potential opportunity to achieve greater production control and avoid some of the environmental concerns of sea farms, many RAS projects have launched around the world in the past decade. However, most of these projects are small, and many have failed or are struggling.

The big problem is cost. RAS facilities need much more capital than ocean farms with similar production rates, and theyre expensive to operate.

Land-based systems use a lot of freshwater, even though its recirculated, and a lot of electricity, notes Couturier. Such systems operate at an economic disadvantage because much of their cost goes toward creating growing conditions occurring naturally within the ocean, summed up one 2014 report that found producing Atlantic salmon in Nova Scotia would not be economically feasible.

AquaBounty, which is buying its Indiana plant from a collapsed RAS venture, expects to beat these odds mainly because its GE salmon reach market size in about half the time of normal farmed salmon in 1618 months rather than 2836 months, the company says. Ravenous as they are, with their growth hormones continually wired on, the fish still require about a quarter less feed than normal fish. (Although farmed salmon are very efficient at converting food to flesh a pound of feed converts to close to a pound of flesh feed remains a major expense.)

The company also says that salmon in its RAS facilities wont need vaccines or antibiotics because it will tightly control conditions. However, they will have some disease issues of course, as will any animal thats reared in high densities, Couturier predicts.

If AquaBounty can compete on cost, there will be some justification for promoting its product as the worlds most sustainable salmon. In addition to requiring less feed, growing fish in Indiana or Prince Edward Island can slash the high carbon costs of flying fish from Norway or Chile, two leading suppliers of farmed salmon in the US.

Still, says Couturier, I wish them all the best, but I think it will be a small-scale niche for at least a decade.

Many aquaculture scientists remain uneasy about the environmental risk to wild ecosystems if transgenic fish slip out of their farms.

Although other agencies will presumably be involved in assessing risk as the projects advance, the FDA has no in-house capacity to evaluate or understand the ecological consequences of transgenics in an aquatic ecosystem, says Conner Bailey, professor emeritus of rural sociology at Auburn University in Alabama. And once you get anything into an aquatic ecosystem, its really hard to control.

AquaBountys protection scheme begins with multiple levels of physical barriers in its RAS facilities. Additionally, the salmon are all female and triploid (their DNA is in three rather than two sets of chromosomes) so they cant reproduce. However, scientists say neither of these measures can be 100 percent effective at preventing transgenic fish from escaping, disrupting local ecosystems and potentially breeding in the wild.

More generally, while AquaBounty is committed to land-based systems, there are concerns that its also creating far more GE eggs than it needs for its own production. Other industry groups, such as the Atlantic Salmon Federation, worry that other producers AquaBounty sells to might not be so careful, or that other companies around the world might move ahead with similar projects but without the same precautions. And all bets on risk are off if GE fish are raised in the ocean, where fish routinely escape, sometimes in large numbers.

Devlins group has extensively modeled the results of accidental releases, studying groups of transgenic and non-transgenic fish in naturalized aquatic test beds that are exposed to variations in conditions, such as food supply. Transgenic fish often behave quite differently, and the results have varied from peaceful coexistence to one experiment in which fully transgenic fish killed off all their competitors.

In the multitude of different environments that exist in nature, the uncertainty is too great to make a reliable prediction of what the impact would be, he says.

Does the fast growth of AquAdvantage salmon justify taking on these unknown risks?

Scientists point out that todays selective breeding research programs, built on genomics and other tools of modern biology, also have turbocharged fish development. Some strains of rainbow trout, which have been selected for fast growth fo
r 150 years, grow incredibly fast compared to wild-type fish, Devlin says. In fact, he says, his lab work across various species suggests that the absolute fastest growth you can achieve either by domestication or by transgenesis seems to be very similar.

Todays farmed salmon have had more than 10 generations of selection applied to them, and they are growing at more than double the rate compared to the 1970s, says Bjarne Gjerde, senior scientist at Nofima in Troms, Norway.

Farmed fish also must excel in many traits besides growth, such as disease resistance and food quality, he emphasizes. Most of the traits we are breeding for are governed by many, many genes with small effects, he says. Thats a real challenge if you just want to take short cuts with genetic engineering.

When and if AquaBounty rises above all its challenges into a groundbreaking success in North America, the firm will send a signal around the world to unleash efforts for commercializing GE fish, observers say.

Friends of the Earths Perls remains hopeful that legal barriers and consumer boycotts will stop AquaBounty in its tracks. If not, GE salmon could set a precedent to the approval of other GE animals in the pipeline, from fish to chickens, pigs and cows, she says. It is critical that we dont approve other GE animals without robust regulations and full environmental reviews to ensure that were prioritizing human and environmental safety over profit.

Fish are probably where transgenic animals will emerge, because its much cheaper to maintain a herd of catfish or salmon than cattle or sheep or pigs, says Bailey.

This story was first published by Ensia, an environmental news magazine from the University of Minnesota.

Here is the original post:
After decades of work, Americans may soon be eating genetically engineered salmon - PRI